Tactiva Therapeutics inks $35 mln Series A
Tactiva Therapeutics, a cancer immunotherapy company, has secured $35 million in Series A financing. Panacea Healthcare Partners led the round with participation from other investors that included Vi Ventures and Efung Capital.
3 December 2018•1 min read
